secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001104659-24-085614
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute receives FDA IND clearance for Phase 3 study of RZ358 in tumor hyperinsulinism
--------------------------------------------------------------------------------

- FDA cleared IND for RZ358 (ersodetug) Phase 3 registrational trial treating hypoglycemia due to tumor HI.
- Double-blind, placebo-controlled study of 24 participants; enrollment expected to start H1 2025.
- Ongoing Phase 3 for congenital HI; topline data anticipated mid-2025.
- Drug is a fully human monoclonal antibody binding to insulin receptor allosteric site.
- Prior Expanded Access Program showed real-world benefit in tumor HI patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924085614/0001104659-24-085614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465924085614/tm2420844d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-085614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer